Physician Views: Our ASCO 2018 preview poll

With the annual ASCO meeting taking place this weekend in Chicago, we are snap-polling attendees from the US and EU5 to ascertain what therapeutic approaches and presentations they are most interested in and which are likely to have the biggest impact on clinical practice (see also ViewPoints: All eyes on ASCO)…

Are you based in an academic or non-academic/community setting?

Academic

Non-academic/community

Which one of the following approaches are you most eager to learn more about at ASCO?

Targeted therapies

PD-(L)1 monotherapies and/or PD-(L)1 combination therapies

Cell therapies (i.e. CAR-Ts)

Cytokines

Other immuno-oncology approaches

Bispecific antibodies

Cancer vaccines

Antibody drug conjugates

Other (please state)

Which one of the following approaches do you think will have the biggest impact on clinical practice over the next five years?

Targeted therapies

PD-(L)1 monotherapies and/or PD-(L)1 combination therapies

Cell therapies (i.e. CAR-Ts)

Cytokines

Other immuno-oncology approaches

Bispecific antibodies

Cancer vaccines

Antibody drug conjugates

Other (please state)

Which one of the following data sets are you most eager to learn more about at ASCO?

Phase I study of LOXO-292 - a highly selective RET Inhibitor for the treatment of patients with RET-altered cancers

Phase III Keynote-042 - Keytruda (pembrolizumab) monotherapy for the first-line treatment of locally advanced or metastatic NSCLC in patients with PD-L1 tumour proportion score (TPS) of at least 1 percent

Phase III Keynote-407 - Keytruda and chemotherapy for the first-line treatment of locally advanced or metastatic squamous NSCLC

Phase III CheckMate-227 - Opdivo (nivolumab) and chemotherapy as well as Opdivo plus Yervoy, versus cheotherapy for the first-line treatment of locally advanced or metastatic NSCLC in patients with PD-L1 TPS of less than 1 percent

Phase III IMPower-131 - Tecentriq (atezolizumab) and chemotherapy for the first-line treatment of locally advanced or metastatic squamous NSCLC

Phase III IMPower-150 - Tecentriq, Avastin (bevacizumab) and chemotherapy for the first-line treatment of locally advanced or metastatic non squamous NSCLC

Phase I study of bb1212 BCMA CAR-T therapy in multiple myeloma

Phase I/II PIVOT study of NKTR-214 and Opdivo in solid tumours

The PD-(L)1 inhibitors - either as monotherapies or in combination with other treatments - have dominated recent ASCO meetings; based on your experience, are you satisfied overall with how clinical promise for these agents has transferred to a real-world setting?

Not at all satisfied

Slightly satisfied

Moderately satisfied

Very satisfied

Extremely satisfied

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

To read more Physician Views articles, click here.

Reference Articles